Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 3

Effect of PS-targeting and anti-PD-1 antibody therapy on survival in a TNBC murine model. Mice with E0771 tumors were treated a total of six times once tumors reached approximately 100 mm3 (days 1, 4, 8, 11, 15, and 18) with single antibody or a combination of mch1N11 and anti-PD-1, and survival times were determined. Once tumors reached approximately 1500 mm3 or animals encountered a tumor-related health problem, animals were euthanized. Survival times were plotted and determined by Kaplan–Meier analysis, statistical analysis was determined by log rank (Mantel–Cox) analysis

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us